EXBIO Antibodies Product Data Sheet

Clone:	BB7.1
Isotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody BB7.1 recognizes the HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
Immunogen:	Papain solubilised HLA-A2, B7
Species Reactivity:	Human, Non-Human Primates
Application:	Flow Cytometry
Purity:	> 95% (by SDS-PAGE)
Purification:	Purified from cell culture supernatant by protein-A affinity chromatography.
Concentration:	1 mg/ml
Storage Buffer:	Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4
Storage / Stability:	Store at 2-8°C. Do not use after expiration date stamped on vial label. For long-term storage aliquot and store at -20°C. Avoid freeze/thaw cycles.
Expiration:	See vial label
Lot Number:	See vial label
Background:	HLA-B7 allele of human HLA class I major histocompatibility (MHC) antigen indicates higher risk of breast cancer and cervical cancer. Expression of HLA-B7 together with HLA-B27 is associated with increased susceptibility to spondyloarthropaties. Flow cytometry detection of these two alleles is being used to screen for patients, who suffer from inflammatory disorders affecting the sacroiliac and intervertebral joints, such as ankylosing spondylosis (AS). The HLA-B7 antigen (11 alleles) is expressed in 22% of healthy Caucasian individuals.
References:	Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis. 2001 Nov 15;184(10):1310-4. Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med. 2004 Mar 15;169(6):696-702. Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B07 and homozygosity of HLA-DQB103. Tissue Antigens. 2007 Oct;70(4):283-93. Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA-B27/HLA-B07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. Clin Exp Rheumatol. 2008 May-Jun;26(3):498-504. Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999 Oct;5(10):2766-72. Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol. 2006 Dec;18(12):1707-18. Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol Cell Proteomics. 2005 Dec;4(12):1888-97. Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. Immunol. 2008 Oct 15;181(8):5442-50. Trapani JA, Vaughan HA, Tait BD, McKenzie IF: Immunoradiometric assay for the rapid detection of HLA-B27. Immunol Cell Biol. 1988 Jan;66 ( Pt 3):215-9. de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002 Jun;128(3):525-31. Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2361-4. Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15;61(18):6868-75. *Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11.

*Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis. 2001 Nov 15;184(10):1310-4.

*Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med. 2004 Mar 15;169(6):696-702.

*Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens. 2007 Oct;70(4):283-93.

*Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA-B*27/HLA-B*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. Clin Exp Rheumatol. 2008 May-Jun;26(3):498-504.

*Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999 Oct;5(10):2766-72.

*Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol. 2006 Dec;18(12):1707-18.

*Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol Cell Proteomics. 2005 Dec;4(12):1888-97.

*Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. Immunol. 2008 Oct 15;181(8):5442-50.

*Trapani JA, Vaughan HA, Tait BD, McKenzie IF: Immunoradiometric assay for the rapid detection of HLA-B27. Immunol Cell Biol. 1988 Jan;66 ( Pt 3):215-9.

*de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002 Jun;128(3):525-31.

*Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2361-4.

*Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15;61(18):6868-75.

*Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11.

11-547-C100

Monoclonal Antibody to HLA-B7
Purified Antibody (0.1 mg)

11-547-C100

Monoclonal Antibody to HLA-B7 Purified Antibody (0.1 mg)

Monoclonal Antibody to HLA-B7
Purified Antibody (0.1 mg)